Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Univariate and multivariate analysis with respect to disease-free survival and overall survival

From: Clinical verification of the relationship between smoking and the immune microenvironment of breast cancer

Parameters Univariate analysis Multivariate analysis
Hazard ratio 95% CI p value Hazard ratio 95% CI p value
Disease-free survival
 Age at operation (year)
  ≤ 56 0.614 0.269–1.335 0.220    
  > 56
 Tumour size (mm)
  ≤ 27.6 1.137 0.525–2.503 0.744    
  > 27.6
 Skin infiltration
  Negative 1.556 0.455–4.067 0.440    
  Positive
 Lymph node status
  Negative 2.440 0.933–8.343 0.071 1.677 0.617–5.859 0.331
  Positive
 Ki67
  Negative 0.394 0.180–0.926 0.034 0.770 0.321–1.942 0.568
  Positive
 Intrinsic subtype
  HER2-enriched 1.884 0.828–4.823 0.135    
  Triple-negative
 ORR
  Non-responders 0.083 0.035–0.210 < 0.001 0.154 0.059–0.426 0.001
  Responders
 Pathological response
  Non-pCR 0.203 0.068–0.499 < 0.001 0.381 0.118–1.059 0.065
  pCR
 TILs
  Low 0.252 0.107–0.553 0.001 0.424 0.167–1.032 0.059
  High
 Pack-years
  Low 0.434 0.127–1.134 0.092 0.567 0.160–1.555 0.289
  High
Overall survival
 Age at operation (year)
  ≤ 56 0.508 0.175–1.338 0.172    
  > 56
 Tumour size (mm)
  ≤ 27.6 1.123 0.429–2.993 0.811    
  > 27.6
 Skin infiltration
  Negative 1.939 0.446–5.977 0.335    
  Positive
 Lymph node status
  Negative 2.778 0.781–17.657 0.125    
  Positive       
 Ki67
  Negative 0.638 0.234–2.023 0.419    
  Positive
 Intrinsic subtype
  HER2-enriched 1.610 0.597–5.060 0.357    
  Triple-negative
 ORR
  Non-responders 0.077 0.026–0.238 < 0.001 0.451 0.044–0.520 0.004
  Responders
 Pathological response
  Non-pCR 0.183 0.042–0.561 0.002 0.282 0.062–0.953 0.041
  pCR
 TILs
  Low 0.357 0.129–0.929 0.035 0.634 0.212–1.861 0.403
  High
 Pack-years
  Low 0.554 0.128–1.700 0.325    
  High
  1. OS overall survival, CI confidence intervals, HER human epidermal growth factor receptor, ORR objective response rate, pCR pathological complete response, TILs tumour-infiltrating lymphocytes